You should know about the latest groundbreaking achievement at the University of Miami’s Miller School of Medicine, where Dr. Jashodeep Datta has been awarded the Joan L. and Julius H. Jacobson II Promising Investigator Award by the American College of Surgeons (ACS). This award is a significant honor, and it’s the first time a surgeon from the Miller School has been recognized with this distinction.
Dr. Datta, an associate professor of surgery, is also the DiMare Family Endowed Chair in Immunotherapy. He specializes in treating patients with pancreatic and liver cancers while simultaneously leading research in immune system interactions with cancer at Sylvester Comprehensive Cancer Center.
A Milestone for the Miller School of Medicine
You’ll appreciate knowing that this award acknowledges Dr. Datta’s remarkable contributions to both surgery and cancer research. His leadership in the field is impressive, particularly in the ways he balances clinical practice and scientific investigation.
The Joan L. and Julius H. Jacobson II Promising Investigator Award is specifically given to surgeons who are seen to be at a tipping point in their career, poised to make major contributions to surgical practice and patient safety.
Dr. Datta is the first surgeon from the Miller School to receive this award, an achievement that brings additional visibility to the institution. As Dr. Datta himself said, “I’m proud of the visibility this will bring to our department and school of medicine.”
An Inspiring Leader in Surgical Oncology
Dr. Datta’s expertise in pancreatic and liver cancer surgeries is only one side of his contributions. His research is focused on the role of the immune system in therapeutic resistance in pancreatic cancer. His efforts are crucial as he co-leads the Gastrointestinal Site Disease Group at Sylvester and serves as the associate director of translational research at the Sylvester Pancreatic Cancer Research Institute.
You’ll also be interested to learn that Dean Henri R. Ford praised Dr. Datta’s work, describing him as a truly deserving recipient of this prestigious honor. “Dr. Datta is a rising star, and we are proud to have him on our team,” he said. Dr. Datta’s achievements reflect the supportive culture fostered at the Miller School, where Dean Ford has championed an environment that drives excellence and innovation.
Fueling Future Research and Discoveries
The $30,000 award that comes with the Jacobson award will be used by Dr. Datta to fund high-risk, high-reward research questions in his lab. This funding is critical in advancing studies that could lead to innovative clinical trials in cancer treatment.
Dr. Datta’s research doesn’t stop here. He has already secured a $2.5 million National Cancer Institute R37 MERIT grant, along with a grant from The V Foundation, to continue examining immune factors in pancreatic cancer. These studies have the potential to lead to new therapies and greatly improve outcomes for patients.
Impact at the Bedside and the Bench
You will find it remarkable that Dr. Datta bridges his clinical work with cutting-edge research. He describes how his surgical experience directly informs his scientific inquiries. “What I do in the operating room has a very close relationship with what I do on the academic side. I derive meaningful questions from the patient’s bedside and bring them back to study deeply in the lab, then bring them back to the patient’s bedside,” he explains.
A Bright Future for Surgical Innovation
The impact of Dr. Datta’s work is further highlighted by Laurence Sands, M.D., M.B.A, the chief of the Division of Colon and Rectal Surgery at the Miller School, who expressed his excitement for Dr. Datta’s future contributions. He pointed out that many previous recipients of the Jacobson award have gone on to become internationally renowned scientists and leaders of large research programs. This positions Dr. Datta not only as a leading figure in surgical oncology but also as a force to watch in the future of cancer research.
The Legacy of the Jacobson Award
Receiving the Joan L. and Julius H. Jacobson II Promising Investigator Award places Dr. Datta among a distinguished group of surgeon-scientists. Many of the past awardees have gone on to achieve international prominence, which suggests a bright future for Dr. Datta’s research and clinical contributions.
The Miller School of Medicine and the Sylvester Comprehensive Cancer Center are fortunate to have such a promising and accomplished individual in their ranks, and you can expect great things from Dr. Datta in the future.
A Deep Commitment to Mentoring the Next Generation of Surgeon-Scientists
You may not realize how central mentorship is to Dr. Datta’s vision for the future of surgical oncology. In his laboratory at Sylvester Comprehensive Cancer Center, he has built a team that includes postdoctoral fellows, surgical residents, graduate students, and medical students who are learning to ask difficult questions about how pancreatic and liver cancers interact with the immune system. Dr. Datta encourages these early-career investigators to take intellectual risks, because the most important breakthroughs often begin with an unexpected result or a question that challenges conventional thinking.
This recognition from the American College of Surgeons reinforces Dr. Datta’s role not only as a clinician and researcher, but also as an educator who is actively shaping the next generation of surgeon-scientists. The Joan L. and Julius H. Jacobson II Promising Investigator Award is designed to identify individuals who are at a pivotal moment in their careers, and mentorship is a key part of that equation. By training young surgeons to move seamlessly between the operating room and the laboratory, Dr. Datta is helping to ensure that translational cancer research remains a central priority in academic surgery for years to come.
Strengthening Translational Immunotherapy for Gastrointestinal Cancers
You’ll be interested to learn that Dr. Datta’s research is focused on one of the most stubborn challenges in modern oncology: why pancreatic and liver cancers so often resist immunotherapy. While immune checkpoint inhibitors have transformed the treatment of melanoma, lung cancer, and several other malignancies, their impact on gastrointestinal cancers has been far more limited. Dr. Datta’s laboratory is working to understand the unique immune-suppressive environment that these tumors create, and how that environment can be reprogrammed to make immunotherapy more effective.
This award provides additional momentum for several lines of investigation that are already underway in Dr. Datta’s group. Among the key areas his team is pursuing are:
- Mapping the immune landscape of pancreatic and liver tumors at single-cell resolution
- Identifying predictive biomarkers that can tell clinicians which patients are most likely to respond to immunotherapy
- Developing novel combination regimens that pair immune checkpoint inhibitors with vaccines, targeted therapies, or local interventions
- Using patient-derived tumor models to test new treatment strategies before they reach clinical trials
By connecting these laboratory discoveries with carefully designed clinical studies, Dr. Datta is working to move the field beyond one-size-fits-all immunotherapy and toward more precise, personalized approaches for patients with difficult-to-treat cancers.
Elevating the Standard of Care Through Multidisciplinary Collaboration
You’ll appreciate knowing that Dr. Datta does not approach pancreatic and liver cancer care in isolation. He is a key member of Sylvester Comprehensive Cancer Center’s multidisciplinary gastrointestinal oncology team, a group that brings together surgeons, medical oncologists, radiation oncologists, pathologists, radiologists, and immunologists on a regular basis. This collaborative structure allows each patient’s case to be reviewed from multiple angles, ensuring that treatment recommendations reflect the full range of available expertise rather than the perspective of a single specialty.
National recognition such as the Jacobson Award can strengthen these collaborations in meaningful ways. When a surgeon is identified as a promising investigator, new opportunities for cross-institutional partnerships, shared data resources, and collaborative grant funding often follow. For Dr. Datta, this means even greater ability to integrate cutting-edge immunotherapy concepts into the surgical care of patients with complex gastrointestinal malignancies, ultimately raising the standard of care both at the Miller School and beyond.
What This Recognition Means for Patients and the South Florida Community
For patients and families facing a pancreatic or liver cancer diagnosis, this national award is more than an institutional milestone. It is a signal that world-class surgical oncology and immunotherapy research is available close to home at the University of Miami’s Miller School of Medicine and Sylvester Comprehensive Cancer Center. Dr. Datta’s ability to combine advanced surgical technique with a deep understanding of tumor immunology means that patients in South Florida can access care that reflects the latest scientific thinking without having to travel to distant academic medical centers.
You should feel reassured that Dr. Datta’s dual focus on operative excellence and scientific discovery translates directly into more personalized treatment options. As new clinical trials open and as biomarker-driven strategies become more refined, eligible patients in the region may gain earlier access to emerging therapies that are not yet widely available. The recognition from the American College of Surgeons underscores that the Miller School is not simply keeping pace with advances in surgical oncology — it is helping to lead them, with direct benefits for the community it serves.